Details for Patent: 8,835,646
✉ Email this page to a colleague
Which drugs does patent 8,835,646 protect, and when does it expire?
Patent 8,835,646 protects ISTURISA and is included in one NDA.
This patent has fifty-three patent family members in thirty-four countries.
Summary for Patent: 8,835,646
| Title: | Organic compounds |
| Abstract: | The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition. |
| Inventor(s): | Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu |
| Assignee: | Recordati SA |
| Application Number: | US13/927,514 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,835,646
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-001 | Mar 6, 2020 | RX | Yes | No | 8,835,646 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-002 | Mar 6, 2020 | RX | Yes | Yes | 8,835,646 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-003 | Mar 6, 2020 | DISCN | Yes | No | 8,835,646 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,835,646
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 057772 | ⤷ Start Trial | |||
| Australia | 2006283105 | ⤷ Start Trial | |||
| Brazil | PI0615095 | ⤷ Start Trial | |||
| Canada | 2619660 | ⤷ Start Trial | |||
| China | 101248078 | ⤷ Start Trial | |||
| China | 102408429 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
